Follicular Lymphoma
Specialty Channel

Featured Article
Long-term follow-up results from the FoRT study shows that the optimal RT dose for patients with indolent NHL is _________.
Fill in the Blank: Long-term follow-up results from the FoRT study show that the optimal radiotherapy dose to treat patients with indolent non-Hodgkin lymphoma is ___ Gy in ___ fractions, according…
Long-term follow-up from the FoRT study shows that the optimal RT dose for patients with indolent NHL and histologic FL or MZL is 24 Gy in 12 fractions.
Study findings lead experts to suggest that the prevalence of DLBCL and FL will likely rise in the United States and Europe, according to research presented at the NCCN Annual Conference.
True or false: The FDA has approved tazemetostat for the treatment of patients with confirmed EZH2-positive relapsed/refractory FL.
The FDA granted accelerated approval to umbralisib for the treatment of adults with relapsed/refractory FL or MZL.
True or false: Tazemetostat has demonstrated durable activity in patients with relapsed/refractory FL and mutations in EZH2.
Rituximab maintenance therapy significantly prolonged PFS in patients with newly diagnosed FL given R-CHOP versus rituximab plus bendamustine, according to data presented at ASH 2020.
The _______ study established that 2 years of rituximab maintenance therapy after first-line immunochemotherapy significantly improves PFS in patients with FL.

News

Long-term follow-up from the FoRT study shows that the optimal RT dose for patients with indolent NHL and histologic FL or MZL is 24 Gy in 12 fractions.
Study findings lead experts to suggest that the prevalence of DLBCL and FL will likely rise in the United States and Europe, according to research presented at the NCCN Annual Conference.
The FDA granted accelerated approval to umbralisib for the treatment of adults with relapsed/refractory FL or MZL.
Rituximab maintenance therapy significantly prolonged PFS in patients with newly diagnosed FL given R-CHOP versus rituximab plus bendamustine, according to data presented at ASH 2020.

Interactive Features

Long-term follow-up results from the FoRT study shows that the optimal RT dose for patients with indolent NHL is _________.
Fill in the Blank: Long-term follow-up results from the FoRT study show that the optimal radiotherapy dose to treat patients with indolent non-Hodgkin lymphoma is ___ Gy in ___ fractions, according…
True or false: The FDA has approved tazemetostat for the treatment of patients with confirmed EZH2-positive relapsed/refractory FL.
True or false: Tazemetostat has demonstrated durable activity in patients with relapsed/refractory FL and mutations in EZH2.
Stay in the know.
OncNet Newsletter